Major Adverse Cardiovascular Events
Also known as: Major Adverse Cardiovascular Event
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB09045 | Dulaglutide | A GLP-1 agonist used to manage type 2 diabetes mellitus. |
| DB06655 | Liraglutide | A GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes. |
| DB06228 | Rivaroxaban | A factor Xa inhibitor used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). May also be used as thrombosis prophylaxis in specific situations. |
| DB01098 | Rosuvastatin | An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke. |
| DB13928 | Semaglutide | A glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB01992 | Coenzyme A | 4 | Recruiting | 1 |
| DB09303 | Evolocumab | 4 | Recruiting | 1 |